HilleVax, Inc. experienced a substantial reduction in its net loss for the first quarter of 2025, reporting a net loss of $6.061 million compared to $46.829 million in the same period last year. This improvement was primarily due to a significant decrease in research and development expenses, largely attributable to the discontinuation of further development of HIL-214 in infants in 2024 and related workforce reductions.

HilleVax reported a net loss of $33.9 million for the fourth quarter of 2024, an improvement from $37.0 million in the same period last year. The company's cash, cash equivalents, and marketable securities stood at $171.4 million as of December 31, 2024. Research and development expenses decreased significantly, while general and administrative expenses saw a slight increase.

HilleVax reported a net loss of $25.8 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $189.3 million as of September 30, 2024. The company is exploring further development of norovirus vaccine candidates and strategic alternatives.

HilleVax reported a net loss of $40.7 million for the second quarter of 2024. The company had $245.0 million in cash, cash equivalents, and marketable securities as of June 30, 2024. They discontinued further development of HIL-214 in infants and announced a workforce reduction of approximately 40%.

HilleVax reported a net loss of $46.8 million for the first quarter of 2024, with $272.7 million in cash, cash equivalents and marketable securities as of March 31, 2024. Topline data from the NEST-IN1 Phase 2B clinical study of HIL-214 in infants is expected in mid-2024.

HilleVax reported financial results for the year ended December 31, 2023. The company had $303.5 million in cash, cash equivalents and marketable securities as of December 31, 2023. Net loss for the fourth quarter 2023 was $37.0 million.

HilleVax reported a net loss of $31.8 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $324.4 million as of September 30, 2023. Research and development expenses for the third quarter 2023 were $27.3 million.

HilleVax reported its financial results for the second quarter of 2023. The company had cash, cash equivalents and marketable securities totaling $244.1 million as of June 30, 2023. Net loss for the second quarter 2023 was $27.9 million, compared to $53.9 million for the second quarter 2022.

HilleVax reported a net loss of $26.9 million for the first quarter of 2023, with cash and cash equivalents totaling $260.5 million as of March 31, 2023. The company's research and development expenses increased to $23.2 million due to the advancement of the HIL-214 program.

HilleVax reported its full year 2022 financial results, highlighting the initiation and execution of the Phase 2b clinical trial NEST-IN1 and the completion of its initial public offering.